{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-001669","form_type":"8-K","ticker":"PMDI","cik":"0000806517","company_name":"PSYCHEMEDICS CORP","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.969624+00:00","generated_at":"2026-06-04T06:49:20.270386+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Psychemedics reports 2023 revenue down 12% to $22.1M, net loss widens to $4.2M","bullets":["Revenue $22.1M in 2023, down 12% from $25.2M in 2022.","Net loss widened to $4.2M ($0.72 per share) from $1.1M loss ($0.19) in 2022.","Cash & equivalents fell to $2.0M from $4.8M at end of 2022.","Operating expenses increased to $11.3M from $10.4M, with G&A rising to $7.2M.","CEO cites ongoing labor shortage; plans cost reductions and pursuit of new markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-001669","json":"https://secwatch.observer/filing/0001171843-24-001669.json","markdown":"https://secwatch.observer/filing/0001171843-24-001669.md","text":"https://secwatch.observer/filing/0001171843-24-001669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/806517/000117184324001669/0001171843-24-001669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/806517/000117184324001669/f8k_032824.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:49:20.270386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba33cf2d6ed8986598eb2524fe2f8cec8351bf55","claim":"PSYCHEMEDICS CORP reported the year ended December 31, 2023 results: revenue $22.1 million, net income net loss of approximately $4.2 million, EPS $0.72 per share.","evidence_excerpt":"but also solidify our position as the leader in the industry,” added Shannon Shoemaker, Chief Revenue Officer. The Company's revenue for the year ended December 31, 2023, was $22.1 million versus $25.2 million for the prior year, a decrease of 12%. As of December 31, 2023, the Company had cash and cash equivalents of approximately $2.0 million, compared with","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/806517/000117184324001669/0001171843-24-001669-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$22.1 million"},{"label":"Net income","value":"net loss of approximately $4.2 million"},{"label":"EPS","value":"$0.72 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}